Sunitinib Treatment Of Renal Adjuvant Cancer (S-TRAC): A Randomized Double Blind Phase 3 Study Of Adjuvant Sunitinib VS. Placebo In Subjects At High Risk Of Recurrent RCC

Status: Active printPrint Results Email Results Save Results
Cancer Type: Kidney Cancer NCT ID: NCT00375674
Trial Phases: Phase III Protocol IDs: A6181109 (primary)
Eligibility: 18 and over, Male and Female Study Type: Treatment
Study Sponsor: Pfizer Incorporated
NCI Full Details:


To compare the disease free survival time and safety of sunitinib with placebo in adjuvant treatment patients at high risk of recurrent kidney cancer after surgery.